News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genelabs Technologies (GNLB) To Present At The Rodman And Renshaw Techvest LLC Global Healthcare Conference



10/19/2005 5:11:10 PM

REDWOOD CITY, Calif., May 3 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that it will present a company update at the Rodman & Renshaw Techvest Global Healthcare Conference at Claridge's Hotel in London on Wednesday, May 12, 2004 at 11:55 a.m. local time.

The presentation is scheduled to be webcast live and may be accessed by going to the Investor Information section of the Genelabs website at http://www.genelabs.com/ or through the following URL: http://www.wallstreetwebcasting.com/webcast/rrshq2/gnlb/ . The presentation will also be available for replay after the presentation for up to 90 days.

Genelabs Technologies, Inc. is a biopharmaceutical company pioneering the discovery and development of novel pharmaceutical products to improve human health. We are concentrating our clinical development capabilities on Prestara(TM), an investigational drug for women with systemic lupus erythematosus and have received an approvable letter for our Prestara New Drug Application from the U.S. Food and Drug Administration. We are concentrating our drug discovery capabilities on novel antiviral compounds for treatment of hepatitis C virus infections.

CONTACT: Matthew M. Loar, Chief Financial Officer of Genelabs Technologies, Inc., +1-650-562-1424.

Genelabs Technologies, Inc.

CONTACT: Matthew M. Loar, Chief Financial Officer of GenelabsTechnologies, Inc., +1-650-562-1424


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES